Molecule intelOpportunity: Lower0

Cilostazol

8 brands · 6 companies · product forms

Opportunity snapshot

Launch attractiveness
28
Market saturation
16
Price room
50
Regulatory risk
0
8
brands
6
companies
Rs 870.7
median price
5
price points
3.01x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 13%

Price room

Across observed sources and strengths
CheapestRs 503.5
MedianRs 870.7
Most expensiveRs 1,516.2
Spread3.01×
Sources: DVAGO, Servaid

max/min price ratio 3.01x across 5 trusted points (Rs 503.5-1516.2). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 3 live products for Cilostazol — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(50) + 20% low-competition(84) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

6 canonical companies and 8 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 3.01x across 5 trusted points (Rs 503.5-1516.2). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.